Perspective Therapeutics, Inc.
No enriched coverage for $CATX in the last 7 days.
No SEC Form 4 filings for $CATX in the last 30 days.
See all $CATX insider activity →Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 s
Perspective Therapeutics (NYSE American: CATX) appointed Paul Lyne, Ph.D. as Chief Science Officer, joining from Merck KGaA. Co-founder Michael K. Schultz, Ph.D. moved to Senior Scientific Advisor. The release cites Lyne’s 25+ years in oncology and work on 30+ oncology programs, and notes Perspective’s clinical-stage radiopharmaceutical pipeline.
Perspective Therapeutics (CATX) has released an analyst presentation detailing its 212Pb-based theranostic pipeline and manufacturing strategy for targeted oncology. The presentation covers its VMT-α-NET program for neuroendocrine tumors and meningioma, highlighting clinical data, a regional manufacturing model for direct-to-hospital delivery, and unaudited financial estimates as of March 31, 2026. This announcement, made via an 8-K filing, outlines the company's approach to expanding market reach and optimizing production of its radiopharmaceutical products.
Recent CATX coverage spans financial news and earnings.
The filing adds concrete runway and a near-term clinical/regulatory timeline for CATX’s lead VMT-α-NET program, which can shift risk/reward for biotech investors.
Leadership transition at a clinical-stage radiopharma can shift R&D execution and near-term investor sentiment, but no pipeline data or guidance changes were disclosed.
The announcement indicates progress in CATX's theranostic pipeline, potentially supporting future growth. The clinical data and manufacturing strategy may enhance market confidence.
The company's upcoming conference participation is unlikely to have a significant immediate impact on its stock price.
Perspective Therapeutics reports strong 2Q 2025 results, highlighting advancements in radiopharmaceutical treatments for cancer. The positive financial update suggests potential upward momentum for the company's stock.
alphai scores every news story that mentions CATX with an AI model for sentiment and relevance, and aggregates insider trades from Perspective Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 s
6 min readPerspective Therapeutics (NYSE American: CATX) appointed Paul Lyne, Ph.D. as Chief Science Officer, joining from Merck KGaA. Co-founder Michael K. Schultz, Ph.D. moved to Senior Scientific Advisor. The release cites Lyne’s 25+ years in oncology and work on 30+ oncology programs, and notes Perspective’s clinical-stage radiopharmaceutical pipeline.
2 min readPerspective Therapeutics (CATX) has released an analyst presentation detailing its 212Pb-based theranostic pipeline and manufacturing strategy for targeted oncology. The presentation covers its VMT-α-NET program for neuroendocrine tumors and meningioma, highlighting clinical data, a regional manufacturing model for direct-to-hospital delivery, and unaudited financial estimates as of March 31, 2026. This announcement, made via an 8-K filing, outlines the company's approach to expanding market reach and optimizing production of its radiopharmaceutical products.
3 min readSEATTLE, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) ( NYSE AMERICAN: CATX ) , a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership ...
2 min readSEATTLE, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective," the "Company," "we," "us," and "our" ) ( NYSE AMERICAN: CATX ) , a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and ...
3 min readSEATTLE, July 24, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) CATX, a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been ...
3 min readSEATTLE, July 24, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) ( NYSE AMERICAN: CATX ) , a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's ...
2 min readSEATTLE, July 15, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) ( NYSE AMERICAN: CATX ) , a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 ...
3 min readSEATTLE, June 21, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) CATX, a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear ...
3 min readSEATTLE, June 21, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) ( NYSE AMERICAN: CATX ) , a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S.
2 min read
